Payment overview · 2025
General Payments
$17.83
1 reported records · 1 companies
Healthcare provider profile · identity verified
Brian O Reese, MD
Allopathic & Osteopathic Physicians|Family Medicine · GORDON, GA · NPI 1629088521
Verified facts
What the public records show
CMS Open Payments records show Brian O Reese, MD received $17.83 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.83 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $17.83 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 669 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 655 | 124 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 583 | 89 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 467 | 100 |
| Omeprazole | Omeprazole | 402 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 43 |
| Montelukast Sodium | Montelukast Sodium | 271 | 50 |
| Gabapentin | Gabapentin | 266 | 62 |
| Losartan Potassium | Losartan Potassium | 262 | 61 |
| Memantine Hcl Er | Memantine Hcl | 258 | 24 |
| Metformin Hcl | Metformin Hcl | 232 | 39 |
| Trazodone Hcl | Trazodone Hcl | 220 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 36 |
| Jardiance | Empagliflozin | 201 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 50 |
| Furosemide | Furosemide | 199 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 43 |
| Sertraline Hcl | Sertraline Hcl | 175 | 29 |
| Benazepril Hcl | Benazepril Hcl | 164 | 21 |
| Carvedilol | Carvedilol | 156 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 28 |
| Famotidine | Famotidine | 146 | 18 |
| Levetiracetam | Levetiracetam | 145 | 13 |
| Potassium Chloride | Potassium Chloride | 142 | 33 |
| Fluconazole | Fluconazole | 137 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 35 |
| Methylprednisolone | Methylprednisolone | 136 | 106 |
| Olanzapine | Olanzapine | 133 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 131 | 18 |
| Donepezil Hcl | Donepezil Hcl | 120 | 12 |
| Simvastatin | Simvastatin | 112 | 24 |
| Divalproex Sodium | Divalproex Sodium | 107 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 45 |
| Lisinopril | Lisinopril | 103 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 96 | 80 |
| Meloxicam | Meloxicam | 93 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 15 |
| Eliquis | Apixaban | 91 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 45 |
| Ibuprofen | Ibuprofen | 88 | 23 |
| Farxiga | Dapagliflozin Propanediol | 87 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 86 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | suppressed |
| Allopurinol | Allopurinol | 73 | 19 |
| Ezetimibe | Ezetimibe | 73 | 22 |
| Naproxen | Naproxen | 73 | 22 |
| Metformin Hcl Er | Metformin Hcl | 71 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 68 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 65 | 13 |
| Memantine Hcl | Memantine Hcl | 65 | suppressed |
| Trulicity | Dulaglutide | 64 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 63 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 13 |
| Tramadol Hcl | Tramadol Hcl | 60 | 17 |
| Sucralfate | Sucralfate | 59 | 19 |
| Alprazolam | Alprazolam | 58 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 50 |
| Ozempic | Semaglutide | 55 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 21 |
| Risperidone | Risperidone | 53 | suppressed |
| Glipizide | Glipizide | 52 | suppressed |
| Colchicine | Colchicine | 51 | 13 |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Carisoprodol | Carisoprodol | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Glimepiride | Glimepiride | 40 | 18 |
| Meclizine Hcl | Meclizine Hcl | 40 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 18 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 36 | suppressed |
| Constulose | Lactulose | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 36 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Clonidine | Clonidine | 32 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 12 |
| Temazepam | Temazepam | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Linzess | Linaclotide | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Primidone | Primidone | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 12 |
| Spironolactone | Spironolactone | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 14 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17.83 · 1 records | PFIZER INC. | VYNDAQEL | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error